Longterm outcome of treatment of Felty's syndrome with intramuscular gold: Case reports and recommendations for management

Journal of Rheumatology

Volumn 32, Issue 1, 2005, Pages 20-26

  Almoallim, Hani ^a,b   Klinkhoff, Alice ^a,c  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b Department of Rheumatology ^*

^c Mary Pack Arthritis Centre   (Canada)

Author keywords

Felty's syndrome; Gold; Leukopenia; Rheumatoid arthritis

Indexed keywords

DISEASE MODIFYING ANTIRHEUMATIC DRUG; GOLD;

ADULT; AGED; APLASIA; CASE REPORT; CLINICAL FEATURE; DERMATITIS; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE CONTROL; DISEASE COURSE; DISEASE DURATION; DRUG EFFECT; DRUG TOLERABILITY; ENTEROCOLITIS; FELTY SYNDROME; FEMALE; GOLD THERAPY; HEPATITIS; HUMAN; INFECTION COMPLICATION; LEUKOCYTE COUNT; LEUKOPENIA; LONG TERM CARE; LUNG INFILTRATE; MALE; MORBIDITY; PRIORITY JOURNAL; RASH; RECURRENT DISEASE; REVIEW; RHEUMATOID ARTHRITIS; RHEUMATOLOGY; STOMATITIS; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ADULT; AGED; ANTIRHEUMATIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FELTY'S SYNDROME; FEMALE; HUMANS; INJECTIONS, INTRAMUSCULAR; LEUKOPENIA; MALE; MIDDLE AGED; ORGANOGOLD COMPOUNDS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 11844274649     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (36)

1. Rosenstein ED, Kramer N. Felty's and pseudo-Felty's syndromes. Semin Arthritis Rheum 1991;21:129-42.
2. Farhey YD, Herman JH. Vasculitis complicating granulocyte colony stimulating factor treatment of leukopenia and infection in Felty's syndrome. J Rheumatol 1995;22:1179-82.
3. Kaprove RE. Felty's syndrome: case report and rationale for disease-suppressant immunosuppressive therapy. J Rheumatol 1981;8:791-6.
4. Dillon AM, Luthra HS, Conn DL, Ferguson RH. Parenteral gold therapy in the Felty syndrome. Experience with 20 patients. Medicine Baltimore 1986;65:107-12.
5. Bellelli A, Veneziani M, Tumiati B. Felty's syndrome: long-term followup after treatment with auranofin. Arthritis Rheum 1987;30:1057-61.
6. Wassenberg S, Herborn G, Rau R. Methotrexate treatment in Felty's syndrome. Br J Rheumatol 1998;37:908-11.
7. Isasi C, Lopez-Martin JA, Angeles Trujillo M, Andreu JL, Palacio S, Mulero J. Felty's syndrome: response to low dose oral methotrexate. J Rheumatol 1989;16:983-5.
8. Allen LS, Groff G. Treatment of Felty's syndrome with low-dose oral methotrexate. Arthritis Rheum 1986;29:902-5.
9. Mant MJ, Akabutu JJ, Herbert FA. Lithium carbonate therapy in severe Felty's syndrome. Benefits, toxicity, and granulocyte function. Arch Intern Med 1986;146:277-80.
10. Breedveld FC, Brand A, van Aken WG. High dose intravenous gamma globulin for Felty's syndrome. J Rheumatol 1985;12:700-2.
11. Krishnaswamy G, Odem C, Chi DS, Kalbfleisch J, Baker N, Smith JK. Resolution of the neutropenia of Felty's syndrome by longterm administration of recombinant granulocyte colony stimulating factor. J Rheumatol 1996;23:763-5.
12. Moore DF Jr, Vadhan-Raj S. Sustained response in Felty's syndrome to prolonged administration of recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF). Am J Med 1995;98:591-4.
13. Talip F, Walker N, Khan W, Zimmermann B. Treatment of Felty's syndrome with leflunomide. J Rheumatol 2001;28:868-70.
14. Gordon DA. Gold and penicillamine. Ruddy S, Harris ED, Sledge CB, Budd RC, Sergent JS, editors. Kelley's textbook of rheumatology. 6th ed. Philadelphia: W.B. Saunders; 2001:869-78.
15. Klinkhoff AV, Teufel A. How low can you go? Use of very low dosage of gold in patients with mucocutaneous reactions. J Rheumatol 1995;22:1657-9.
16. Arthur AB. Klinkhoff A, Teufel A. Nitritoid reactions: case reports, review, and recommendations for management. J Rheumatol 2001;28:2209-12.
17. Sibley JT, Haga M, Visram DA, Mitchell DM. The clinical course of Felty's syndrome compared to matched controls. J Rheumatol 1991;18:1163-7.
18. Lanchbury JS, Jaeger EE, Sansom DM, et al. Strong primary selection for the Dw4 subtype of DR4 accounts for the HLA-DQw7 association with Felty's syndrome. Hum Immunol 1991;32:56-64.
19. Wordsworth P, Pile KD, Buckely JD, et al. HLA heterozygosity contributes to susceptibility to rheumatoid arthritis. Am J Hum Genet 1992;51:585-91.
20. Coakley G, Brooks D, Iqbal M, et al. Major histocompatibility complex haplotypic associations in Felty's syndrome and large granular lymphocyte syndrome are secondary to allelic association with HLA-DRB 1*0401. Rheumatology Oxford 2000;39:393-8.
21. Starkebaum G, Arena WP, Nardella FA, Gavin SE. Characterization of immune complexes and immunoglobulin G antibodies reactive with neutrophils in the sera of patients with Felty's syndrome. J Lab Clin Med 1980;96:238-51.
22. Dancey JT, Brubaker LH. Neutrophil marrow profiles in patients with rheumatoid arthritis and neutropenia. Br J Haematol 1979;43:607-17.
23. Meliconi R, Uguccioni M, Chieco-Bianchi F, et al. The role of interleukin-8 and other cytokines in the pathogenesis of Felty's syndrome. Clin Exp Rheumatol 1995;13:285-91.
24. Coakley G, Mok CC, Hajeer AH, et al. Interleukin-10 promoter polymorphisms in rheumatoid arthritis and Felty's syndrome. Br J Rheumatol 1998;37:988-91.
25. Coakley G, Iqbal M, Brooks D, Panayi GS, Lanchbury JS. CD8+, CD57+ T cells from healthy elderly subjects suppress neutrophil development in vitro: implications for the neutropenia of Felty's and large granular lymphocyte syndromes. Arthritis Rheum 2000;43:834-43.
26. Hellmich B, Csernok E, Schatz H, Gross WL, Schnabel A. Autoantibodies against granulocyte colony-stimulating factor in Felty's syndrome and neutropenic systemic lupus erythematosus. Arthritis Rheum 2002;46:2384-91.
27. Kumakura S, Kobayashi S, Ishikura H. Neutrophil phagocytosis in Felty's syndrome. Am J Med 2001;111:579-80.
28. Cohen MG, Webb J. Antihistone antibodies in rheumatoid arthritis and Felty's syndrome. Arthritis Rheum 1989;32:1319-24.
29. Coremans IE, Hagen EC, van der Voort EA, van der Woude FJ, Daha MR, Breedveld FC. Autoantibodies to neutrophil cytoplasmic enzymes in Felty's syndrome. Clin Exp Rheumatol 1993;11:255-62.
30. Campion G, Maddison PJ, Goulding N, et al. The Felty syndrome: a case-matched study of clinical manifestations and outcome, serologic features, and immunogenetic associations. Medicine Baltimore 1990;69:69-80.
31. Thorne C, Urowitz MB. Long-term outcome in Felty's syndrome. Ann Rheum Dis 1982;41:486-9.
32. Breedveld FC, Fibbe WE, Hermans J, van der Meer JW, Cats A. Factors influencing the incidence of infections in Felty's syndrome. Arch Intern Med 1987;147:915-20.
33. Hellmich B, Csernok E, de Haas M, et al. Low Fc gamma receptor III and high granulocyte colony-stimulating factor serum levels correlate with the risk of infection in neutropenia due to Felty's syndrome or systemic lupus erythematosus. Am J Med 2002;113:134-9.
34. Huizinga TW, de Haas M, Kleijer M, Nuijens JH, Roos D, von dem Borne AE. Soluble Fc gamma receptor III in human plasma originates from release by neutrophils. J Clin Invest 1990;86:416-23.
35. Huizinga TW, de Haas M, van Oers MH, et al. The plasma concentration of soluble Fc-gamma RIII is related to production of neutrophils. Br J Haematol 1994;87:459-63.
36. Doran MF, Crowson CS, Pond GR, O'Fallon WM, Gabriel SE. Predictors of infection in rheumatoid arthritis. Arthritis Rheum 2002;46:2294-300.